Certara (NASDAQ:CERT) Raised to Buy at UBS Group

UBS Group upgraded shares of Certara (NASDAQ:CERT) from a neutral rating to a buy rating in a research note published on Friday, Marketbeat reports. They currently have $16.00 price target on the stock.

CERT has been the subject of a number of other research reports. Barclays dropped their price target on Certara from $18.00 to $16.00 and set an equal weight rating for the company in a research report on Friday, June 28th. JMP Securities restated a market perform rating on shares of Certara in a research report on Wednesday, July 10th. KeyCorp dropped their price objective on shares of Certara from $23.00 to $20.00 and set an overweight rating for the company in a report on Thursday, July 11th. Finally, Robert W. Baird reduced their target price on Certara from $19.00 to $18.00 and set a neutral rating on the stock in a research note on Wednesday, August 7th. Six equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Certara currently has an average rating of Hold and a consensus price target of $17.79.

Certara Stock Up 9.8 %

CERT stock opened at $11.75 on Friday. The stock has a 50-day simple moving average of $12.73 and a two-hundred day simple moving average of $15.06. Certara has a twelve month low of $10.35 and a twelve month high of $19.87. The firm has a market capitalization of $1.89 billion, a PE ratio of -30.13, a PEG ratio of 5.17 and a beta of 1.49. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last posted its earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $93.31 million during the quarter, compared to analysts’ expectations of $96.01 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The business’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.10 earnings per share. On average, equities analysts predict that Certara will post 0.27 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares of the company’s stock, valued at $1,125,658.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.39% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Mubadala Investment Co PJSC purchased a new stake in Certara during the 4th quarter valued at $169,135,000. Wasatch Advisors LP boosted its holdings in shares of Certara by 23.4% during the first quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock worth $88,056,000 after purchasing an additional 932,598 shares during the period. Geneva Capital Management LLC raised its position in Certara by 15.1% during the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock valued at $78,747,000 after purchasing an additional 579,349 shares during the last quarter. Clearbridge Investments LLC raised its holdings in shares of Certara by 0.8% during the first quarter. Clearbridge Investments LLC now owns 4,173,195 shares of the company’s stock valued at $74,617,000 after acquiring an additional 32,846 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Certara by 9.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock worth $42,643,000 after purchasing an additional 273,095 shares during the period. Institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.